Biodexa Pharmaceuticals (BDRX) Long-Term Deferred Tax (2015 - 2025)

Biodexa Pharmaceuticals (BDRX) has 11 years of Long-Term Deferred Tax data on file, last reported at $27.3 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Deferred Tax rose 6.76% year-over-year to $27.3 million; the trailing twelve-month figure through Dec 2025 stood at $27.3 million (up 6.76% YoY), and the FY2025 full-year result was $27.0 million, up 5.82% from the prior year.
• Long-Term Deferred Tax rose to $27.3 million in Q4 2025, from $25.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $27.3 million in Q4 2025 to a low of $21.0 million in Q4 2022.
• A 5-year average of $24.0 million and a median of $23.5 million in 2023 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax jumped 978.3% in 2021 and decreased 7.84% in 2022, its largest moves.
• Tracing BDRX's Long-Term Deferred Tax over 5 years: stood at $22.8 million in 2021, then retreated by 7.84% to $21.0 million in 2022, then advanced by 11.73% to $23.5 million in 2023, then increased by 8.88% to $25.5 million in 2024, then gained by 6.76% to $27.3 million in 2025.
• Business Quant data shows BDRX's Long-Term Deferred Tax at $27.3 million in Q4 2025, $25.5 million in Q4 2024, and $23.5 million in Q4 2023.